Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 5, 2015, Pages 204.e1-204.e7

  Gandhi, Nilay M ^a   Baras, Alexander ^a   Munari, Enrico ^a   Faraj, Sheila ^a   Reis, Leonardo O ^a   Liu, Jen Jane ^a   Kates, Max ^a   Hoque, Mohammad Obaidul ^a   Berman, David ^b   Hahn, Noah M ^a   Eisenberger, Mario ^a   Netto, George J ^a   Schoenberg, Mark P ^c   Bivalacqua, Trinity J ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b QUEEN S UNIVERSITY   (Canada)

^c MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Bladder cancer; Gemcitabine cisplatin; Neoadjuvant chemotherapy; Pathologic response; Urothelial carcinoma

Indexed keywords

CISPLATIN; GEMCITABINE; DEOXYCYTIDINE;

ADULT; AGED; ALGORITHM; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SPECIFIC SURVIVAL; CANCER SURGERY; COHORT ANALYSIS; CONTROLLED STUDY; CYSTECTOMY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MUSCLE INVASIVE BLADDER CANCER; OUTCOME ASSESSMENT; PATHOLOGIC RESPONSE; PATHOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; MIDDLE AGED; NEOADJUVANT THERAPY; PROCEDURES; SURVIVAL RATE; UROLOGIC NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CISPLATIN; COHORT STUDIES; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; OUTCOME ASSESSMENT (HEALTH CARE); SURVIVAL RATE; UROLOGIC NEOPLASMS;

EID: 84929264615     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2015.02.011     Document Type: Article

References (21)

1. Grossman H.B., Natale R.B., Tangen C.M., Speights V.O., Vogelzang N.J., Trump D.L., et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003, 349:859-866.
2. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 2003, 361:1927-1934. Advanced Bladder Cancer (ABC) Meta-Analysis Collaboration.
3. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data: advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005, 48:202-205. Advanced Bladder Cancer (ABC) Meta-Analysis Collaboration.
4. Griffiths G., Hall R., Sylvester R., Raghavan D., Parmar M.K. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011, 29:2171-2177.
5. Gray P.J., Fedewa S.A., Shipley W.U., Efstathiou J.A., Lin C.C., Zietman A.L., et al. Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Database. Eur Urol 2013, 63:823-829.
6. Liew M.S., Azad A., Tafreshi A., Eapen R., Bolton D., Davis I.D., et al. USANZ: time-trends in use and impact on outcomes of perioperative chemotherapy in patients treated with radical cystectomy for urothelial bladder cancer. BJU Int 2013, 112:74-82.
7. Sternberg C.N., de Mulder P., Schornagel J.H., Theodore C., Fossa S.D., van Oosterom A.T., et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumors. Eur J Cancer 2006, 42(1):50-54.
8. Von der Maase H., Sengelov L., Roberts J.T., Ricci S., Dogliotti L., Oliver T., et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005, 23:4602-4608.
9. Zaid H.B., Patel S.G., Stimson C.J., Resnick M.J., Cookson M.S., Barocas D.A., et al. Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: results from the National Cancer Database. Urology 2014, 83:75-80.
10. Apolo A.B., Kim J.W., Bochner B.H., Steinberg S.M., Bajorin D.F., Kelly K., et al. Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States. Urol Oncol 2014, 10.1016/j.urolonc.2013.12.012.
11. Bochner B.H., Feifer A., Sperling D., et al. Multi-institutional quality care initiative (QCI) to improve the care of patients with invasive bladder cancer. J Clin Oncol 2014, 32(Suppl. 4). [abstr 298].
12. Reese A.C., Ball M.W., Gandhi N., Gorin M.A., Netto G.J., Bivalacqua T.J., et al. The utility of an extensive postchemotherapy staging evaluation in patients receiving neoadjuvant chemotherapy for bladder cancer. Urology 2014, 84:358-364.
13. Choi W., Porten S., Kim S., Willis D., Plimack E.R., Hoffman-Censits J., et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer 2014, 25:152-165.
14. Eldefrawy A., Soloway M.S., Katkoori D., Singal R., Pan D., Manoharan M. Neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer: the likelihood of initiation and completion. Indian J Urol 2012, 28:424-426.
15. National Comprehensive Cancer Network. Bladder cancer (version 2). ; 2014. http://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf.
16. Choueiri T.K., Jacobus S., Bellmunt J., Qu A., Appleman L.J., Tretter C., et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol 2014, 32:1889-1894.
17. Sonpavde G., Goldman B.H., Speights V.O., Lerner S.P., Wood D.P., Vogelzang N.J., et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer 2009, 115:4104-4109.
18. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014, 507:315-322.
19. Van Allen E.M., Mouw K.W., Kim P., Iyer G., Wagle N., Al-Ahmadie H., et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov 2014, 4:1140-1153.
20. Zarger H., Espiritu P.N., Fairey A.S., Mertens L.S., Dinney C.P., Mir M.C., et al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol 2014, pii: S0302-2838(14)00893-8 [Epub ahead of print]. 10.1016/j.eururo.2014.09.007.
21. Plimack E.R., Hoffman-Censits J.H., Viterbo R., Trabulsi E.J., Ross E.A., Greenberg R.E., et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol 2014, 32:1895-1901.